comparemela.com

Latest Breaking News On - Gabriel lopez berestein - Page 1 : comparemela.com

Comparing Bio-Path (NASDAQ:BPTH) and RVL Pharmaceuticals (NASDAQ:RVLP)

Bio-Path (NASDAQ:BPTH – Get Rating) and RVL Pharmaceuticals (NASDAQ:RVLP – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability. Profitability This table compares Bio-Path and RVL Pharmaceuticals’ net margins, […]

StockNews com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Equities researchers at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a research report issued on Thursday. The firm set a “sell” rating on the stock. Separately, Roth Capital reaffirmed a “buy” rating on shares of Bio-Path in a report on Friday, March 17th. Bio-Path Stock Performance Shares of NASDAQ:BPTH opened […]

Bio-Path Holdings, Inc (NASDAQ:BPTH) Sees Large Growth in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 74,700 shares, a growth of 6.1% from the April 30th total of 70,400 shares. Based on an average daily volume of 29,600 shares, the short-interest ratio is […]

Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a report released on Wednesday morning. The firm issued a sell rating on the stock. Separately, Roth Capital reiterated a buy rating on shares of Bio-Path in a research report on Friday, March 17th. Bio-Path Price Performance Shares of NASDAQ:BPTH opened at $1.65 […]

StockNews com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Investment analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock. Separately, Roth Capital reaffirmed a “buy” rating on shares of Bio-Path in a research note on Friday, March 17th. Bio-Path Stock Performance NASDAQ BPTH […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.